Biologic characteristics of bone marrow–derived mesenchymal stem cells from a patient with thalassemia syndrome

Yoon, Jae Sung; Kim, E. S.; Hwang, Dae-Suk; Choi, Jin-Won; Kim, B. K.; Park, Byung Bae; Choi, Jin Hee; Lee, Y. Y.

doi:10.1111/j.1751-553x.2010.01285.x

Cited by 3 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs of patients with NMHD were able to equally differentiate into osteoblasts and chondrocytes as MSCs of healthy donors. Similar results for MSCs of patients with thalassemia [29,30] and SCD [32,34] were reported. Interestingly, we observed that MSCs of all four tested patients with thalassemia differentiated less well into adipocytes than MSCs of other NMHD and control group.…”

Section: Discussionsupporting

confidence: 85%

“…Consent results with ours were reported in 2 single reports: one for SCD [35] and one for congenital idiopathic neutropenia [37]. In contrast, Yoon et al [29] in their study with only one thalassemia patient found a normal immunosuppressive potential. Our results showed a significantly impaired immunosuppressive potential of TM-MSCs at the MNC:MSC ratio 1:1 compared to healthy control.…”

Section: Discussionsupporting

confidence: 55%

“…However, MSCs of patients with non-malignant hematological diseases have been less well studied. In contrast to MSCs generated from patients with aplastic anemia (AA), which have been thoroughly investigated [22][23][24][25][26][27][28], MSCs from patients with thalassemia and SCD are poorly characterized [29][30][31][32][33][34][35], whereas MSCs generated from patients with congenital neutropenia are not studied at all. In the current study, we show for the first time that bone marrow of thalassemia patients contain a significantly higher number of mononuclear cells (BM-MNCs) than the bone marrow of healthy donors.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast to a handful of reports on MSCs from patients with anemia, there are only three reports on MSCs of patients with thalassemia. According to Yoon et al [29], who reported data from one patient, there is no difference in the quality of MSCs as morphology, phenotype, proliferation, trilineage differentiation potential and immunosuppression in mixed lymphocyte reaction (MLR) compared to control. Aksoy et al [30] reported that MSCs from thalassemia patients exerted also a higher proliferation potential than MSCs of healthy donors.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Phenotype and Functional Activity of Mesenchymal Stromal Cells in Pediatric Patients with Non-Malignant Hematological Diseases

Kuçi

Jordan

Wehner

et al. 2020

Cells

View full text Add to dashboard Cite

As the biology of mesenchymal stromal cells (MSCs) in patients with non-malignant hematological diseases (NMHD) is poorly understood, in the current study we performed a basic characterization of the phenotype and functional activity of NMHD-MSCs. Bone marrow (BM) of patients with thalassemia major (TM) possessed a significantly higher number of nucleated cells (BM-MNCs)/mL BM than healthy donors (P < 0.0001), which however did not result in a higher number of colony forming units-fibroblast (CFU-F) per milliliter BM. In contrast, from 1 × 106 BM-MNCs of patients with sickle cell disease (SCD) were generated significantly more CFU-Fs than from TM-BM-MNCs (P < 0.013) and control group (P < 0.02). In addition, NMHD-MSCs expressed significantly lower levels of CD146 molecule, demonstrated an equal proliferation potential and differentiated along three lineages (osteoblasts, chondrocytes and adipocytes) as healthy donors’ MSCs, with exception of TM-MSCs which differentiated weakly in adipocytes. In contrast to other NMHD-MSCs and healthy donors’ MSCs, TM-MSCs demonstrated an impaired in vitro immunosuppressive potential, either. Noteworthy, the majority of the immunosuppressive effect of NMHD-MSCs was mediated through prostaglandin-E2 (PGE2), because indomethacin (an inhibitor of PGE2 synthesis) was able to significantly reverse this effect. Our results indicate therefore that NMHD-MSCs, except TM-MSCs, may be used as an autologous cell-based therapy for post-transplant complications such as graft failure, graft-versus-host disease (GvHD) and osteonecrosis.

show abstract